Agenda of 10th Round ACTA negotiations, August 16-20, Washington DC
USTR will host the next round of ACTA negotiations that will take place all of next week, August 16-20, in Washington DC. According to USTR yesterday, the negotiators “expect to cover all issues” and the agenda would be made available in a day or so.
Here is a proposed agenda that we have obtained from another source.
ANTI-COUNTERFEITING TRADE AGREEMENT (ACTA)
PROPOSED AGENDA
10th Round of Negotiations
August 16th-20th, 2010, Washington, DCACTA’s Washington DC conclave: Is this Round 10?
According to an informed source, USTR intimated that next week’s ACTA meeting in Washington DC will be attended by all the negotiating parties and that discussions would include all issues under consideration in ACTA. We are still awaiting a response from USTR regarding the attendees, scope and purpose of the meeting but this new information seems to be indicative of nothing short of the next ACTA round.
Earlier, US government officials had informed that the an intersessional meeting would be held the week of 16 August in Washington DC.
Continue ReadingWHO releases names of experts and advisor to the Emergency Committee concerning Influenza Pandemic (H1N1) 2009
WHO has released the ‘List of Members of, and Advisor to, the International Health Regulations (2005) Emergency Committee concerning Influenza Pandemic (H1N1) 2009‘ at the following site: http://www.who.int/ihr/emerg_comm_members_2009/en/. Of the 15 members and one advisor, 6 had declaration of interests. On this matter, WHO had the following statement:
Sources for Researching Drug Prices
The following are links to web pages with prices of prescription drugs.
Australia
Schedule Pharmaceutical Benefits
http://www.pbs.gov.au/html/home pageAustria
The Common European Drug Database (CEDD)
http://cedd.oep.hu/Bahrain
National Health Regulatory Authority
http://www.nhra.bh/SitePages/View.aspx?PageId=42Belgium
Institut National D’Assurance Maladie-Invalidité Pharmanet
http://www.inami.fgov.be/fr/statistiques/medicament/Pages/statistiques-medicaments-pharmacies-pharmanet.aspx#.WaV_VSeQxQK
Continue ReadingThe US Orphan Drug Tax Credit
From the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading
The US Orphan Drug Tax Credit
From the FDA page on the Orphan Drug Tax Credit.
IncentivesTAX CREDIT
(See Footnote 1 below)
FOR TESTING EXPENSES FOR
DRUGS FOR RARE DISEASES OR CONDITIONSIntroduction
Section 45C of the Internal Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical testing expenses related to the use of a drug for a rare disease or condition after it is designated as an orphan drug.2010 Fabrazyme March-In Request
NIH rejects Fabrazyme March-In Petition
- December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying the drug in a timely manner.
- December 7, 2010. Statements by KEI and others on NIH rejection of Fabrazyme March-In Request
1 ACTA briefing by De Gucht in the European Parliament
This week, the European Commission conducted two briefings for members of the European Parliament.
On Monday, July 12, members of the European Parliament’s INTA Committee (Committee on International Trade) were briefed by EU ACTA negotiators Luc Devigne and Pedro Valesco in a private, closed meeting.
Today, July 13, Karel De Gucht, EU Commissioner for Trade held a public briefing in the LIBE Committee (Committee on Civil Liberties, Justice and Home Affairs). The video is now available here
China describes TRIPS Council proposal on ACTA and other plurilateral enforcement agreements.
At a June 28, 2010 Geneva workshop on the Anti-Counterfeiting Trade Agreement. Dr. Zhao Hong, from the Permanent Mission of the People’s Republic of China to the World Trade Organization, distributed a proposal that was prepared for the June 8-9, 2010 meeting of the WTO TRIPS Council:
Decisions to be takenDecision of the TRIPS Council on the Relationship between the TRIPS Agreement and Intellectual Property Provisions of bilateral, plurilteral Trade Agreeements
Members,
4 The EU proposal for increasing access?
The EU position came out in a proposal for a Joint Recommendation with 9 articles in 11 pages. It is hard to believe but it is worst than the US proposal and it is even worst than nothing. It is an outrageous “roll back” recommendation. It does make clear who’s the boss in the commission. The publishers apparently. Their proposal is bold. Here’s a quick read: